Dr. Jen-Tang (JT) Lu *17, the founder and CEO of Vysioneer, leads the innovation at the intersection of AI and medicine. His startup, Vysioneer, is on a mission to bring cancer therapies to patients sooner. VBrain, the company’s flagship product, is the first AI tumor auto-contouring solution to gain FDA approval, offering revolutionary technology for pharmaceutical companies and clinics to improve precision in cancer care.

Before founding Vysioneer, JT served as a machine learning scientist at the Mass General Brigham’s AI center. There, he significantly enhanced patient care for spinal diseases and aortic aneurysms by developing and deploying large-scale, deep learning-based products into the clinical workflow. His academic achievements include earning a Ph.D. in Electrical Engineering from Princeton University, where he focused on developing algorithms and systems for medical imaging applications, particularly in optical and ultrasound imaging technology. His pioneering work earned him the Top Prize at the Princeton Innovation Forum in 2016. In 2023, his entrepreneurial spirit was further recognized when he became a co-winner of the Alumni Startup Challenge, affirming his significant contributions to both the Princeton community and the broader medical technology sector.

Through his work with Vysioneer, JT exemplifies the powerful combination of AI and medicine, driving advancements in oncology that promise to enhance patient care and treatment outcomes. His commitment to leveraging AI for cancer treatment underscores his leadership in the ongoing technological revolution, striving to make cancer treatment more precise, efficient, and accessible to patients around the world.